Clinical Trial Update: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing insulin efsitora alfa (LY3209590) with insulin glargine in adults with type 2 diabetes starting basal insulin for the first time has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Efsitora Alfa (LY3209590)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes, T2D | Phase 3 | Status: COMPLETED | Results posted: 2025-08-06